Spotlight on Rheumatology

Credits: 1.00 CME
Research Updates in Gout: Improving Response Rate to Therapy
Brian Mandell, MD, PhD
Annenberg Center for Health Sciences at Eisenhower

Research Updates in Gout: Improving Response Rate to Therapy

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: February 12, 2021
Expires: February 11, 2022
60 minutes to complete

Accredited By

Target Audience

Rheumatologists, nephrologists, and other healthcare professionals involved in the care of patients with gout.

Learning Objectives

  • Summarize the latest evidence related to combination pharmacologic treatment of patients with gout who do not achieve the target serum urate level with monotherapy
  • Summarize the latest evidence related to complications associated with gout
  • Incorporate evidence-based research into clinical practice

Activity Description

OVERVIEW
Dr. Brian Mandell and Dr. Naomi Schlesinger discuss recent published evidence related to gout, as well as study results presented at the American College of Rheumatology Convergence 2020 virtual annual meeting. Dr. Schlesinger begins with an introduction to this CME activity by touching on a recent published systematic review indicating that the manifestations of gout extend beyond the joints, affecting other organs and tissues. Dr. Schlesinger also provides an overview of some of the challenges encountered in clinical practice with the use of urate-lowering therapy. In module 1, Dr. Schlesinger focuses on 2 abstracts presented at ACR Convergence 2020 concerning gout-related comorbidities, particularly cardiovascular disease. In module 2, Dr. Mandell focuses on 2 abstracts related to the safety and use of urate-lowering therapy, specifically allopurinol, febuxostat, and pegloticase. In module 3, Dr. Mandell discusses 2 abstracts related to the systemic nature of gout; 1 abstract focuses on heart failure, while the other focuses on the lumbar spine.

CONTENT AREAS

  • Systemic burden of gout
  • Gout comorbidities
  • Allopurinol
  • Febuxostat
  • Pegloticase

Statement of Educational Need

  • Increased understanding of the safety and efficacy of combination treatment with medications with different mechanisms for lowering the serum urate level
  • Increased understanding of updated recommendations regarding the use of combination urate-lowering therapy
  • Increased understanding of the association of gout with systemic complications involving the heart, kidneys, and other organs

Agenda

Modules will be structured and recorded in a manner that best supports the nature of the data published by each study. In general, this structure will be:

  1. Faculty welcomes the learner, introduces the study, states why the study was included in this program [1 min]
  2. Faculty reviews study methodology [1 min]
    1. For emphasis or clarity, charts, graphs, or PowerPoint slides may be edited into the final video
  3. Faculty summarizes key findings [3-4 min]
    1. How the data advances the current treatment landscape/paradigms
    2. How the data should be positioned among ongoing research
    3. How the data connects with current research imperatives
    4. Clinical significance/implications for current knowledge or practice
    5. Data one might be expected from the trial in the future
  4. Faculty provides commentary [5-8 min]

Note: this structure may vary slightly when two smaller studies or abstracts are presented in the same module.

Faculty

Brian Mandell, MD, PhD
Professor of Medicine
Chairman of Academic Medicine
Cleveland Clinic
Cleveland, Ohio


Naomi Schlesinger, MD
Professor of Medicine
Chief, Division of Rheumatology
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey

Conflict of Interest Policy/Disclosure Statement

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Faculty
Brian Mandell, MD, PhD
Consultant: Horizon
Data Monitoring Safety Board: Horizon
Speakers Bureau: Genentech

Naomi Schlesinger, MD
Advisory Board: IFM, Johnson and Johnson
Research Support: Amgen, Pfizer
Speakers Bureau: Horizon

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.

The estimated time to complete the activity is 1.0 hour.

Statement of Commercial Support

This activity is supported by an educational grant from Horizon Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.

Additional content planners
The following have no significant relationship to disclose:
Greg Scott, PharmD (Medical writer)
Eugene Cullen, MD (Peer Reviewer)

Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Contact Information for Questions About the Activity

For help or questions about this activity please contact Continuing Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: February 12, 2021
Expires: February 11, 2022
60 minutes to complete

Accredited By

Target Audience

Rheumatologists, nephrologists, and other healthcare professionals involved in the care of patients with gout.

Learning Objectives

  • Summarize the latest evidence related to combination pharmacologic treatment of patients with gout who do not achieve the target serum urate level with monotherapy
  • Summarize the latest evidence related to complications associated with gout
  • Incorporate evidence-based research into clinical practice

Activity Description

OVERVIEW
Dr. Brian Mandell and Dr. Naomi Schlesinger discuss recent published evidence related to gout, as well as study results presented at the American College of Rheumatology Convergence 2020 virtual annual meeting. Dr. Schlesinger begins with an introduction to this CME activity by touching on a recent published systematic review indicating that the manifestations of gout extend beyond the joints, affecting other organs and tissues. Dr. Schlesinger also provides an overview of some of the challenges encountered in clinical practice with the use of urate-lowering therapy. In module 1, Dr. Schlesinger focuses on 2 abstracts presented at ACR Convergence 2020 concerning gout-related comorbidities, particularly cardiovascular disease. In module 2, Dr. Mandell focuses on 2 abstracts related to the safety and use of urate-lowering therapy, specifically allopurinol, febuxostat, and pegloticase. In module 3, Dr. Mandell discusses 2 abstracts related to the systemic nature of gout; 1 abstract focuses on heart failure, while the other focuses on the lumbar spine.

CONTENT AREAS

  • Systemic burden of gout
  • Gout comorbidities
  • Allopurinol
  • Febuxostat
  • Pegloticase

Statement of Educational Need

  • Increased understanding of the safety and efficacy of combination treatment with medications with different mechanisms for lowering the serum urate level
  • Increased understanding of updated recommendations regarding the use of combination urate-lowering therapy
  • Increased understanding of the association of gout with systemic complications involving the heart, kidneys, and other organs

Agenda

Modules will be structured and recorded in a manner that best supports the nature of the data published by each study. In general, this structure will be:

  1. Faculty welcomes the learner, introduces the study, states why the study was included in this program [1 min]
  2. Faculty reviews study methodology [1 min]
    1. For emphasis or clarity, charts, graphs, or PowerPoint slides may be edited into the final video
  3. Faculty summarizes key findings [3-4 min]
    1. How the data advances the current treatment landscape/paradigms
    2. How the data should be positioned among ongoing research
    3. How the data connects with current research imperatives
    4. Clinical significance/implications for current knowledge or practice
    5. Data one might be expected from the trial in the future
  4. Faculty provides commentary [5-8 min]

Note: this structure may vary slightly when two smaller studies or abstracts are presented in the same module.

Faculty

Brian Mandell, MD, PhD
Professor of Medicine
Chairman of Academic Medicine
Cleveland Clinic
Cleveland, Ohio


Naomi Schlesinger, MD
Professor of Medicine
Chief, Division of Rheumatology
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey

Conflict of Interest Policy/Disclosure Statement

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Faculty
Brian Mandell, MD, PhD
Consultant: Horizon
Data Monitoring Safety Board: Horizon
Speakers Bureau: Genentech

Naomi Schlesinger, MD
Advisory Board: IFM, Johnson and Johnson
Research Support: Amgen, Pfizer
Speakers Bureau: Horizon

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.

The estimated time to complete the activity is 1.0 hour.

Statement of Commercial Support

This activity is supported by an educational grant from Horizon Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.

Additional content planners
The following have no significant relationship to disclose:
Greg Scott, PharmD (Medical writer)
Eugene Cullen, MD (Peer Reviewer)

Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Contact Information for Questions About the Activity

For help or questions about this activity please contact Continuing Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday

Rheumatology Presentations

0.75 CME
Integrity Continuing Education, Inc.
Virtual “Escape Rheum”: A Case-Based Guide to Diagnosis and Management of Pulmonary Arterial Hypertension Associated with Connective Tissue Disease

Virtual “Escape Rheum”: A Case-Based Guide to Diagnosis and Management of Pulmonary Arterial Hypertension Associated with Connective Tissue Disease

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: October 1, 2021
Expires: October 1, 2022
45 minutes to complete

Accredited By

Target Audience

This educational activity has been designed to meet the needs of rheumatology health care providers, including doctors, nurse practitioners, physician assistants, and other healthcare providers involved in the management of patients with CTD-PAH.

Learning Objectives

  • Recognize that patients with CTD are at increased risk for developing PAH.
  • Discuss the best practices for screening, diagnosis, classification, functional capacity classification, and utilization of echocardiography, and right heart catheterization (RHC) in CTD-PAH.
  • Review the clinical trial data, safety, efficacy, and side effect profiles of existing therapeutics for the management of PAH in the treatment of CTD-PAH based on evidence-based medicine and expert consensus.
  • Promote collaboration and care coordination across the multidisciplinary care team to optimize treatment in patients with CTD-PAH.
  • Identify communication strategies for promoting disease-understanding and shared decision-making among patients and caregivers to encourage them to take an active role in the disease management process.

Activity Description

Simulation Activity

Statement of Educational Need

Patients with rheumatic diseases are at higher risk of pulmonary arterial hypertension (PAH) secondary to their conditions. Rheumatologists should maintain a high index of suspicion for PAH in their patients with systemic sclerosis and other mixed connective tissue disorders. This activity will present recommendations for routine screening of patients in a rheumatology practice for PAH as well as the basics of diagnosis and management of PAH. This educational activity will review the epidemiology, pathophysiology, and diagnostic strategies of PAH in patients with connective tissue diseases (CTD). Additionally, faculty will discuss which PAH therapies are beneficial for patients with CTD-PAH and the importance of a multidisciplinary team in managing these patients.

During this interactive online activity, learners listen to a brief lecture given by national faculty experts on diagnosis, staging, and treatment of patients with CTD-PAH. Learners will then enter an online escape room where they will be presented with a patient that they will work to diagnose and treat by answering clinical content questions to earn clues and lab results regarding their patient. Once they have treated the patient to the standard of care, the patient will be sent home with appropriate patient education and referrals to supportive care.

Faculty

Flavia Castelino, MD
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts


Victor Tapson, MD
Professor of Medicine
Department of Pulmonary & Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Flavia Castelino, MD
No real or apparent conflicts of interest to disclose.

Victor Tapson, MD
Advisory Board: Actelion, Bayer, Johnson & Johnson, United Therapeutics
Research funding to institution: Actelion, Johnson & Johnson, United Therapeutics
Study Steering Committee: Bayer

The Integrity Continuing Education planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of October 1, 2021 through October 1, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the post-test and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.

Statement of Commercial Support

This program is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceuticals Company of Johnson & Johnson.

Disclaimer Statement

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: October 1, 2021
Expires: October 1, 2022
45 minutes to complete

Accredited By

Target Audience

This educational activity has been designed to meet the needs of rheumatology health care providers, including doctors, nurse practitioners, physician assistants, and other healthcare providers involved in the management of patients with CTD-PAH.

Learning Objectives

  • Recognize that patients with CTD are at increased risk for developing PAH.
  • Discuss the best practices for screening, diagnosis, classification, functional capacity classification, and utilization of echocardiography, and right heart catheterization (RHC) in CTD-PAH.
  • Review the clinical trial data, safety, efficacy, and side effect profiles of existing therapeutics for the management of PAH in the treatment of CTD-PAH based on evidence-based medicine and expert consensus.
  • Promote collaboration and care coordination across the multidisciplinary care team to optimize treatment in patients with CTD-PAH.
  • Identify communication strategies for promoting disease-understanding and shared decision-making among patients and caregivers to encourage them to take an active role in the disease management process.

Activity Description

Simulation Activity

Statement of Educational Need

Patients with rheumatic diseases are at higher risk of pulmonary arterial hypertension (PAH) secondary to their conditions. Rheumatologists should maintain a high index of suspicion for PAH in their patients with systemic sclerosis and other mixed connective tissue disorders. This activity will present recommendations for routine screening of patients in a rheumatology practice for PAH as well as the basics of diagnosis and management of PAH. This educational activity will review the epidemiology, pathophysiology, and diagnostic strategies of PAH in patients with connective tissue diseases (CTD). Additionally, faculty will discuss which PAH therapies are beneficial for patients with CTD-PAH and the importance of a multidisciplinary team in managing these patients.

During this interactive online activity, learners listen to a brief lecture given by national faculty experts on diagnosis, staging, and treatment of patients with CTD-PAH. Learners will then enter an online escape room where they will be presented with a patient that they will work to diagnose and treat by answering clinical content questions to earn clues and lab results regarding their patient. Once they have treated the patient to the standard of care, the patient will be sent home with appropriate patient education and referrals to supportive care.

Faculty

Flavia Castelino, MD
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts


Victor Tapson, MD
Professor of Medicine
Department of Pulmonary & Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Flavia Castelino, MD
No real or apparent conflicts of interest to disclose.

Victor Tapson, MD
Advisory Board: Actelion, Bayer, Johnson & Johnson, United Therapeutics
Research funding to institution: Actelion, Johnson & Johnson, United Therapeutics
Study Steering Committee: Bayer

The Integrity Continuing Education planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of October 1, 2021 through October 1, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the post-test and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.

Statement of Commercial Support

This program is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceuticals Company of Johnson & Johnson.

Disclaimer Statement

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

1.00 CME
Vindico Medical Education
The Changing Landscape of Immune-Based Therapies for COVID-19

The Changing Landscape of Immune-Based Therapies for COVID-19

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: September 29, 2021
Expires: September 28, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, rheumatologists, and other health care professionals involved in the management of patients hospitalized with COVID-19 infection.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Describe the clinical and immunological events underlying the natural history of COVID-19.
  • Critically appraise the data regarding immune-based therapies for the management of hyperinflammation due to COVID-19, including glucocorticoids, Janus kinase inhibitors, and other targeted agents.
  • Describe how variables such as disease severity, timing, and immunologic endotypes should impact the management of patients hospitalized with COVID-19 infection.

Activity Description

The COVID-19 pandemic has led to a health care crisis with widespread global morbidity and mortality, spurring unprecedented levels of ongoing research for effective therapeutic strategies. A major challenge for health care providers involved in patient management is staying current on the latest evidence-based care despite the rapid influx of data. Hospitalists and other clinicians who care for hospitalized patients may rely heavily on therapies with which they are familiar, namely corticosteroids. However, immunomodulatory therapies such as Janus kinase inhibitors and interleukin-6 inhibitors provide promising options to prevent disease progression and reduce mortality risk. In this educational activity, multidisciplinary panel members review the clinical and immunological events underlying COVID-19; appraise emerging data on immunomodulatory therapies; and discuss how disease severity, timing, and immunological endotypes may impact the management of patients hospitalized with COVID-19 infection.

Agenda

Introduction and Immunopathogenesis of COVID-19
Leonard H. Calabrese, DO

Updates on Immune-Based Therapies for the Management of Patients With COVID-19
Kevin Winthrop, MD, MPH

Considerations for Outpatient Management of Immunocompromised Patients
Cassandra Calabrese, DO

Putting it All Together: How Should We Manage Patients Hospitalized With COVID-19?
D. Clark Files, MD

Conclusion
Leonard H. Calabrese, DO

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee:
AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Pfizer, Regeneron, Sanofi Genzyme, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Regeneron, Sanofi, UCB

Faculty

Cassandra Calabrese, DO
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Disclosure:
Speakers Bureau: Sanofi-Genzyme


D. Clark Files, MD
Associate Professor
Pulmonary, Critical Care, Allergy, and Immunologic Diseases
Wake Forest School of Medicine
Winston-Salem, NC

Disclosure:
Consulting Fee: California Institute of Regenerative Medicine
Data Safety Monitoring Board: Medpace


Kevin Winthrop, MD, MPH
Professor, Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Sciences University
Portland, OR

Disclosure:
Consulting Fee: Horizon, Insmed, Paratek, Red Hill Biopharma, Spero
Contracted Research: Insmed

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: September 29, 2021
Expires: September 28, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, rheumatologists, and other health care professionals involved in the management of patients hospitalized with COVID-19 infection.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Describe the clinical and immunological events underlying the natural history of COVID-19.
  • Critically appraise the data regarding immune-based therapies for the management of hyperinflammation due to COVID-19, including glucocorticoids, Janus kinase inhibitors, and other targeted agents.
  • Describe how variables such as disease severity, timing, and immunologic endotypes should impact the management of patients hospitalized with COVID-19 infection.

Activity Description

The COVID-19 pandemic has led to a health care crisis with widespread global morbidity and mortality, spurring unprecedented levels of ongoing research for effective therapeutic strategies. A major challenge for health care providers involved in patient management is staying current on the latest evidence-based care despite the rapid influx of data. Hospitalists and other clinicians who care for hospitalized patients may rely heavily on therapies with which they are familiar, namely corticosteroids. However, immunomodulatory therapies such as Janus kinase inhibitors and interleukin-6 inhibitors provide promising options to prevent disease progression and reduce mortality risk. In this educational activity, multidisciplinary panel members review the clinical and immunological events underlying COVID-19; appraise emerging data on immunomodulatory therapies; and discuss how disease severity, timing, and immunological endotypes may impact the management of patients hospitalized with COVID-19 infection.

Agenda

Introduction and Immunopathogenesis of COVID-19
Leonard H. Calabrese, DO

Updates on Immune-Based Therapies for the Management of Patients With COVID-19
Kevin Winthrop, MD, MPH

Considerations for Outpatient Management of Immunocompromised Patients
Cassandra Calabrese, DO

Putting it All Together: How Should We Manage Patients Hospitalized With COVID-19?
D. Clark Files, MD

Conclusion
Leonard H. Calabrese, DO

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee:
AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Pfizer, Regeneron, Sanofi Genzyme, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Regeneron, Sanofi, UCB

Faculty

Cassandra Calabrese, DO
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Disclosure:
Speakers Bureau: Sanofi-Genzyme


D. Clark Files, MD
Associate Professor
Pulmonary, Critical Care, Allergy, and Immunologic Diseases
Wake Forest School of Medicine
Winston-Salem, NC

Disclosure:
Consulting Fee: California Institute of Regenerative Medicine
Data Safety Monitoring Board: Medpace


Kevin Winthrop, MD, MPH
Professor, Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Sciences University
Portland, OR

Disclosure:
Consulting Fee: Horizon, Insmed, Paratek, Red Hill Biopharma, Spero
Contracted Research: Insmed

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.00 CME
Vindico Medical Education
SSc-ILD Podcast Series: Clinical Updates to Manage a Rare Lung Condition

SSc-ILD Podcast Series: Clinical Updates to Manage a Rare Lung Condition

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: August 31, 2021
Expires: August 30, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, rheumatologists, dermatologists, and other health care professionals involved in the management of patients with systemic sclerosis-associated interstitial lung disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Examine the prevalence, risk factors, and disease course of systemic sclerosis-associated interstitial lung disease (SSc-ILD).
  • Evaluate strategies to ensure timely screening and monitoring for early diagnosis of patients with SSc-ILD.
  • Review treatment options based on clinical evidence and expert guidelines.
  • Assess communication strategies to help facilitate effective management, self-care and adherence in patients with SSc-ILD.

Activity Description

In this 4-part podcast series, expert faculty review best practices for the screening and diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD). They will also review the current and emerging therapies and the clinical evidence supporting their use in SSc-ILD.

Statement of Educational Need

Systemic sclerosis (SSc) is a rare multisystem autoimmune disorder with estimated incidence and prevalence estimates in the United States of 15.1 per 100,000 person-years and 25.9 per 100,000 people, respectively. In SSc, sclerosis of the skin, vasculopathy, and damage to internal organs including the lungs develop results from a complex interplay between vascular injury, fibrotic processes and immunological pathways. Lung involvement is the leading cause of SSc-associated death. Lung fibrosis develops in 80% of patients, and 25% to 30% develop progressive interstitial lung disease (ILD), leading to a 10-year mortality of up to 40% in those affected. It is thus crucial that clinicians can recognize and diagnose SSc-associated ILD (SSc-ILD) early to initiate appropriate therapy in a timely manner. Clinicians must also be abreast of the most recent treatment guidelines and the current and emerging therapies for SSc-ILD so they can plan optimal treatment plans for their patients.

Agenda

Understanding SSc-ILD: Prevalence and Burden of Disease With Drs. Elizabeth Volkmann and Kevin Flaherty

Diagnosis of SSc-ILD: Screening and Monitoring of Lung Function With Drs. Elizabeth Volkmann and Kristin Highland

Management of SSc-ILD: Guidelines and Treatment Options With Drs. Elizabeth Volkmann and Kevin Flaherty

Improving Adherence: Patient Engagement and Education With Drs. Elizabeth Volkmann and Kristin Highland

Activity Chair

Elizabeth R. Volkmann, MD, MS
Associate Professor of Medicine
Director, UCLA Scleroderma Program
Co-Director, CTD-ILD Program
Division of Rheumatology
Department of Medicine
University of California, Los Angeles
Los Angeles, CA

Disclosure: Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Boehringer Ingelheim
Contracted Research: Kadmon

Faculty

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Disclosure: Consulting Fee: Arrowhead, AstraZeneca, Bellerophon, Boehringer Ingelheim, DevPro, FibroGen, Horizon, Lupin, Pliant, Polarean, PureHealth, PureTech, Respivant, Shionogi, Sun, United Therapeutics
Contracted Research: Boehringer Ingelheim


Kristin B. Highland, MD, MSCR
Director, Rheumatic Lung Disease Program
Cleveland Clinic
Cleveland, OH

Disclosure: Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Actelion, Bayer, Boehringer Ingelheim, United Therapeutics
Contracted Research: Acceleron, Actelion, Bayer, Boehringer Ingelheim, Gossamer Bio, United Therapeutics, Viela Bio

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

ADA Compliance

In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this Podcast is available upon request. Requests should include the Podcast title and can be emailed to CME@VindicoCME.com. Requests will be honored within 3-5 business days.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: August 31, 2021
Expires: August 30, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, rheumatologists, dermatologists, and other health care professionals involved in the management of patients with systemic sclerosis-associated interstitial lung disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Examine the prevalence, risk factors, and disease course of systemic sclerosis-associated interstitial lung disease (SSc-ILD).
  • Evaluate strategies to ensure timely screening and monitoring for early diagnosis of patients with SSc-ILD.
  • Review treatment options based on clinical evidence and expert guidelines.
  • Assess communication strategies to help facilitate effective management, self-care and adherence in patients with SSc-ILD.

Activity Description

In this 4-part podcast series, expert faculty review best practices for the screening and diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD). They will also review the current and emerging therapies and the clinical evidence supporting their use in SSc-ILD.

Statement of Educational Need

Systemic sclerosis (SSc) is a rare multisystem autoimmune disorder with estimated incidence and prevalence estimates in the United States of 15.1 per 100,000 person-years and 25.9 per 100,000 people, respectively. In SSc, sclerosis of the skin, vasculopathy, and damage to internal organs including the lungs develop results from a complex interplay between vascular injury, fibrotic processes and immunological pathways. Lung involvement is the leading cause of SSc-associated death. Lung fibrosis develops in 80% of patients, and 25% to 30% develop progressive interstitial lung disease (ILD), leading to a 10-year mortality of up to 40% in those affected. It is thus crucial that clinicians can recognize and diagnose SSc-associated ILD (SSc-ILD) early to initiate appropriate therapy in a timely manner. Clinicians must also be abreast of the most recent treatment guidelines and the current and emerging therapies for SSc-ILD so they can plan optimal treatment plans for their patients.

Agenda

Understanding SSc-ILD: Prevalence and Burden of Disease With Drs. Elizabeth Volkmann and Kevin Flaherty

Diagnosis of SSc-ILD: Screening and Monitoring of Lung Function With Drs. Elizabeth Volkmann and Kristin Highland

Management of SSc-ILD: Guidelines and Treatment Options With Drs. Elizabeth Volkmann and Kevin Flaherty

Improving Adherence: Patient Engagement and Education With Drs. Elizabeth Volkmann and Kristin Highland

Activity Chair

Elizabeth R. Volkmann, MD, MS
Associate Professor of Medicine
Director, UCLA Scleroderma Program
Co-Director, CTD-ILD Program
Division of Rheumatology
Department of Medicine
University of California, Los Angeles
Los Angeles, CA

Disclosure: Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Boehringer Ingelheim
Contracted Research: Kadmon

Faculty

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Disclosure: Consulting Fee: Arrowhead, AstraZeneca, Bellerophon, Boehringer Ingelheim, DevPro, FibroGen, Horizon, Lupin, Pliant, Polarean, PureHealth, PureTech, Respivant, Shionogi, Sun, United Therapeutics
Contracted Research: Boehringer Ingelheim


Kristin B. Highland, MD, MSCR
Director, Rheumatic Lung Disease Program
Cleveland Clinic
Cleveland, OH

Disclosure: Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Actelion, Bayer, Boehringer Ingelheim, United Therapeutics
Contracted Research: Acceleron, Actelion, Bayer, Boehringer Ingelheim, Gossamer Bio, United Therapeutics, Viela Bio

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

ADA Compliance

In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this Podcast is available upon request. Requests should include the Podcast title and can be emailed to CME@VindicoCME.com. Requests will be honored within 3-5 business days.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.00 AANP / CME
AKH Inc., Advancing Knowledge in Healthcare
PsA+COVID-19: Augmented Reality and Patient Engagement in the Treatment of Psoriatic Arthritis

PsA+COVID-19: Augmented Reality and Patient Engagement in the Treatment of Psoriatic Arthritis

Start

Activity Details

Free CME/AANP
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 21, 2021
Expires: June 21, 2022
60 minutes to complete

Accredited By

This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.

Target Audience

The target audiences are rheumatologists and nurse practitioner (NP)/physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with psoriatic arthritis (PsA) can benefit from participation in this education.

Learning Objectives

As a result of participation in this initiative, participants will increase their ability to:

  1. Use augmented reality (AR) apps for providers and patients on mechanisms of action (MOAs) of therapies for treatment of PsA.
  2. Discuss effectiveness and safety of conventional, biologic, and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
  3. Apply evolving recommendations and clinical practice guidelines related to COVID-19 infection and vaccination to providing care to patients with PsA.
  4. Inform patients with PsA about the impact of their disease and the benefits and risks of medications in the context of COVID-19 infection and vaccination when making shared decisions about treatment plan and treatment modifications.

Activity Description

COVID-19 has impacted PsA patient care in many ways, particularly for patients with multiple comorbidities. This interactive activity reviews clinical practice guidelines addressing COVID-19 infection and vaccination that are relevant to patients with PsA, highlights effectiveness and safety of therapies for PsA, and offers a self-directed experience of building and solving patient cases to learn from making decisions and receiving immediate feedback. This activity also incorporates the patient perspective, a skill-oriented presentation on engaging patients in shared decision making, decision aids, and a demonstration of an augmented reality (AR) app on PsA for healthcare providers and patients.

Please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device to gain the most benefit from participation in this activity. You may use this QR code or search for it in Google Play or the App Store.

For the best experience, use a laptop, desktop, or tablet with the Google Chrome browser.

Agenda

  1. Providing Psoriatic Arthritis Care During the COVID-19 Pandemic
  2. Using Shared Decision Making to Engage Patients With Psoriatic Arthritis to Clarify Treatment Goals in the Context of COVID-19
  3. Demonstration of Augmented Reality App for Providers and Patients
  4. Personalized Patient Cases

Faculty

Atul A. Deodhar, MD, MRCP, FACR, FACP
Professor of Medicine,
Medical Director of Rheumatology Clinics,
Division of Arthritis & Rheumatic Diseases
Oregon Health & Science University
Portland, Oregon


Richard Martin, MD, MA
Professor of Medicine and Rheumatology,
Michigan State University College of Human Medicine
Grand Rapids, Michigan


David Kramer
Patient Presenter

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies.* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.

*The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies—unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.

The following individuals have indicated that they have not had, in the past 24 months, a relevant financial relationship(s) with ineligible companies to disclose:

  • Planners (Forefront Collaborative): Leah Johnson and Marianna Shershneva, MD, PhD
  • Planners (Faculty): Linda Grinnell-Merrick, MS, NP-BC
  • Patient Presenter: David Kramer
  • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN, and Bernadette Marie Makar, MSN, APRN, BC, NP-C

The following individuals have disclosed that they have had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:

Faculty Presenter: Atul A. Deodhar, MD, MRCP, FACR, FACP

  • Consultant: Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, GlaxoSmithKline, Galapagos, Novartis, Pfizer, UCB
  • Speaker: Eli Lilly, Janssen, Novartis, Pfizer
  • Independent contractor (including contracted research): AbbVie, Amgen, Celgene, Eli Lilly, GlaxoSmithKline, Galapagos, Novartis, Pfizer, UCB

Faculty Presenter: Richard Martin, MD, MA

  • Contracted Research/Current Clinical Trials: AbbVie, Eli Lilly

Faculty Planner: Alvin F. Wells, MD, PhD, FACR

  • Speakers Bureau: AbbVie, Amgen, BMS, Eli Lilly, Novartis, Pfizer, Sanofi

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Physicians
Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

This activity is approved for 1.0 contact hour (which includes 0.25 hours of pharmacology).

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include references to unlabeled or unapproved uses of drugs.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

Activity Details

Free CME/AANP
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 21, 2021
Expires: June 21, 2022
60 minutes to complete

Accredited By

This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.

Target Audience

The target audiences are rheumatologists and nurse practitioner (NP)/physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with psoriatic arthritis (PsA) can benefit from participation in this education.

Learning Objectives

As a result of participation in this initiative, participants will increase their ability to:

  1. Use augmented reality (AR) apps for providers and patients on mechanisms of action (MOAs) of therapies for treatment of PsA.
  2. Discuss effectiveness and safety of conventional, biologic, and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
  3. Apply evolving recommendations and clinical practice guidelines related to COVID-19 infection and vaccination to providing care to patients with PsA.
  4. Inform patients with PsA about the impact of their disease and the benefits and risks of medications in the context of COVID-19 infection and vaccination when making shared decisions about treatment plan and treatment modifications.

Activity Description

COVID-19 has impacted PsA patient care in many ways, particularly for patients with multiple comorbidities. This interactive activity reviews clinical practice guidelines addressing COVID-19 infection and vaccination that are relevant to patients with PsA, highlights effectiveness and safety of therapies for PsA, and offers a self-directed experience of building and solving patient cases to learn from making decisions and receiving immediate feedback. This activity also incorporates the patient perspective, a skill-oriented presentation on engaging patients in shared decision making, decision aids, and a demonstration of an augmented reality (AR) app on PsA for healthcare providers and patients.

Please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device to gain the most benefit from participation in this activity. You may use this QR code or search for it in Google Play or the App Store.

For the best experience, use a laptop, desktop, or tablet with the Google Chrome browser.

Agenda

  1. Providing Psoriatic Arthritis Care During the COVID-19 Pandemic
  2. Using Shared Decision Making to Engage Patients With Psoriatic Arthritis to Clarify Treatment Goals in the Context of COVID-19
  3. Demonstration of Augmented Reality App for Providers and Patients
  4. Personalized Patient Cases

Faculty

Atul A. Deodhar, MD, MRCP, FACR, FACP
Professor of Medicine,
Medical Director of Rheumatology Clinics,
Division of Arthritis & Rheumatic Diseases
Oregon Health & Science University
Portland, Oregon


Richard Martin, MD, MA
Professor of Medicine and Rheumatology,
Michigan State University College of Human Medicine
Grand Rapids, Michigan


David Kramer
Patient Presenter

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies.* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.

*The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies—unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.

The following individuals have indicated that they have not had, in the past 24 months, a relevant financial relationship(s) with ineligible companies to disclose:

  • Planners (Forefront Collaborative): Leah Johnson and Marianna Shershneva, MD, PhD
  • Planners (Faculty): Linda Grinnell-Merrick, MS, NP-BC
  • Patient Presenter: David Kramer
  • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN, and Bernadette Marie Makar, MSN, APRN, BC, NP-C

The following individuals have disclosed that they have had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:

Faculty Presenter: Atul A. Deodhar, MD, MRCP, FACR, FACP

  • Consultant: Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, GlaxoSmithKline, Galapagos, Novartis, Pfizer, UCB
  • Speaker: Eli Lilly, Janssen, Novartis, Pfizer
  • Independent contractor (including contracted research): AbbVie, Amgen, Celgene, Eli Lilly, GlaxoSmithKline, Galapagos, Novartis, Pfizer, UCB

Faculty Presenter: Richard Martin, MD, MA

  • Contracted Research/Current Clinical Trials: AbbVie, Eli Lilly

Faculty Planner: Alvin F. Wells, MD, PhD, FACR

  • Speakers Bureau: AbbVie, Amgen, BMS, Eli Lilly, Novartis, Pfizer, Sanofi

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Physicians
Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

This activity is approved for 1.0 contact hour (which includes 0.25 hours of pharmacology).

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include references to unlabeled or unapproved uses of drugs.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

1.00 CME / MOC
Forefront Collaborative
Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control—Share, Learn, Engage: Novel Targeted Therapies in the Treatment of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control—Share, Learn, Engage: Novel Targeted Therapies in the Treatment of Systemic Lupus Erythematosus

Start

Activity Details

Free CME/ABIM MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Part II Points
Released: May 21, 2021
Expires: May 21, 2022
60 minutes to complete

Accredited By

Target Audience

The primary target audience for this activity is rheumatologists who practice in the United States (US) and outside the US. Other rheumatology providers and other clinicians who treat patients with systemic lupus erythematosus (SLE) can benefit from participation.

Learning Objectives

As a result of participation in this educational activity, participants should be able to:

  • Discuss immunopathogenesis of SLE in relation to novel targeted therapies.
  • Translate available and emerging clinical trial data and outcomes into clinically meaningful information for providing care to patients with SLE.
  • Explain data about treatment options to patient with SLE.

Activity Description

Immerse yourself in this 60-minute interactive activity to meet a patient with systemic lupus erythematosus (SLE), view concise presentations, and engage in hands-on experience with the content. This activity will highlight the immunopathogenesis of SLE and mechanisms of action of therapies. Additionally, leading clinical experts will review clinical trial data and outcomes, both available and emerging, and translate them into clinically meaningful information for patient care. This activity is one of two in the series, Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control.

For the best experience, use a laptop, desktop, or tablet with the Google Chrome browser.

Faculty

Sheetal Desai, MD, MSEd
Chief of Rheumatology,
Rheumatology Fellowship Program Director,
Director, Lupus Clinic
Associate Clinical Professor of Medicine,
Division of Rheumatology
University of California, Irvine
Irvine, California


Bevra H. Hahn, MD
Distinguished Professor of Medicine (Emeritus),
Division of Rheumatology
University of California, Los Angeles
Los Angeles, California


Lauren Irving
Patient Presenter

Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Marianna Shershneva, MD, PhD, and Megan Ragan
  • Presenter: Lauren Irving

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Presenter: Sheetal Desai, MD, MSEd

  • Advisory Board: Janssen, GlaxoSmithKline
  • Speakers Bureau: Janssen, GlaxoSmithKline

Presenter: Bevra H. Hahn, MD

  • Advisory Board: Janssen
  • Consulting Fee: Aurinia
  • Data Safety Monitoring: UCB

CME Content Review

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

ACCME: Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™; physicians should claim only the creditcommensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

UEMS-EACCME®: The UEMS-EACCME® has an agreement of mutual recognition of AMA PRA Category 1 Credit(s)™. International physicians interested in converting AMA PRA Category 1 Credit(s)™ to EACCME credit should contact the UEMS, https://www.uems.eu/.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Activity Details

Free CME/ABIM MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Part II Points
Released: May 21, 2021
Expires: May 21, 2022
60 minutes to complete

Accredited By

Target Audience

The primary target audience for this activity is rheumatologists who practice in the United States (US) and outside the US. Other rheumatology providers and other clinicians who treat patients with systemic lupus erythematosus (SLE) can benefit from participation.

Learning Objectives

As a result of participation in this educational activity, participants should be able to:

  • Discuss immunopathogenesis of SLE in relation to novel targeted therapies.
  • Translate available and emerging clinical trial data and outcomes into clinically meaningful information for providing care to patients with SLE.
  • Explain data about treatment options to patient with SLE.

Activity Description

Immerse yourself in this 60-minute interactive activity to meet a patient with systemic lupus erythematosus (SLE), view concise presentations, and engage in hands-on experience with the content. This activity will highlight the immunopathogenesis of SLE and mechanisms of action of therapies. Additionally, leading clinical experts will review clinical trial data and outcomes, both available and emerging, and translate them into clinically meaningful information for patient care. This activity is one of two in the series, Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control.

For the best experience, use a laptop, desktop, or tablet with the Google Chrome browser.

Faculty

Sheetal Desai, MD, MSEd
Chief of Rheumatology,
Rheumatology Fellowship Program Director,
Director, Lupus Clinic
Associate Clinical Professor of Medicine,
Division of Rheumatology
University of California, Irvine
Irvine, California


Bevra H. Hahn, MD
Distinguished Professor of Medicine (Emeritus),
Division of Rheumatology
University of California, Los Angeles
Los Angeles, California


Lauren Irving
Patient Presenter

Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Marianna Shershneva, MD, PhD, and Megan Ragan
  • Presenter: Lauren Irving

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Presenter: Sheetal Desai, MD, MSEd

  • Advisory Board: Janssen, GlaxoSmithKline
  • Speakers Bureau: Janssen, GlaxoSmithKline

Presenter: Bevra H. Hahn, MD

  • Advisory Board: Janssen
  • Consulting Fee: Aurinia
  • Data Safety Monitoring: UCB

CME Content Review

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

ACCME: Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™; physicians should claim only the creditcommensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

UEMS-EACCME®: The UEMS-EACCME® has an agreement of mutual recognition of AMA PRA Category 1 Credit(s)™. International physicians interested in converting AMA PRA Category 1 Credit(s)™ to EACCME credit should contact the UEMS, https://www.uems.eu/.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

1.25 AANP / CME
AKH Inc., Advancing Knowledge in Healthcare
PsA+COVID-19: Virtual Solutions and Personalized Learning That Optimize Psoriatic Arthritis Care

PsA+COVID-19: Virtual Solutions and Personalized Learning That Optimize Psoriatic Arthritis Care

Start

Activity Details

Free CME/AANP
1.25 AMA PRA Category 1 Credit(s)
1.25 Contact Hour(s)
Released: April 12, 2021
Expires: April 12, 2022
75 minutes to complete

Accredited By

This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.

Target Audience

The target audience for this activity is rheumatologists and nurse practitioner (NP) and physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation in this education.

Learning Objectives

As a result of participation in this educational activity, participants should increase their ability to:

  • Summarize mechanisms of action (MOAs), effectiveness, and safety of conventional, targeted synthetic, and biologic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
  • Explain reasons to stop/delay treatment vs reasons to initiate/continue PsA treatment in elderly patients and patients with comorbidities in the context of COVID-19.
  • Discuss the role of telemedicine and other virtual strategies and tools to remotely monitor PsA progression and manage patients with PsA during and following the time of the COVID-19 pandemic.

Activity Description

The COVID-19 pandemic has added uncertainty and complexity to providing care to patients with psoriatic disease. Appropriate use of strategies and tools that support providing rheumatology care remotely is critical in today’s clinical encounters. This educational activity addresses these issues through a variety of innovative experiences. First, Dr. Philip Mease and Dr. Alvin Wells present a fascinating look at immune activation and targeted therapies in psoriatic arthritis (PsA) through augmented reality. Participants are invited to join this experience via their mobile device. The activity also features a concise overview of the latest American College of Rheumatology’s clinical practice guidelines related to COVID-19, a self-directed exercise in building and exploring patient cases, and best practices for telemedicine.

To gain the most benefit from participation in this activity, please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device. You may use one of the QR codes below or search for it in the Google Play or App Store. You may also find it helpful to download and print the worksheet from the Resources section before starting the activity.

Agenda

  1. Augmented Reality Experience: The Main Pathways of Immune Activation and Targeted Therapies in Psoriatic Arthritis
  2. Treatment of Psoriatic Arthritis During the COVID-19 Pandemic
  3. Personalized Patient Cases
  4. Telemedicine: Best Practices, and Tools to Overcome the Constraints of Distance, Location, and Time

Faculty

Philip Mease, MD, MACR
Director, Rheumatology Research
Swedish Medical Center/Providence St. Joseph Health
Clinical Professor,
University of Washington School of Medicine
Seattle, Washington


Alvin F. Wells, MD, PhD, FACR
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Director, Aurora Rheumatology and Immunotherapy Center
Franklin, Wisconsin
Adjunct Assistant Professor, Duke University Medical Center
Durham, North Carolina
Assistant Clinical Professor, Medical College of Wisconsin
Milwaukee, Wisconsin

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this activity.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Leah Johnson, Marianna Shershneva, MD, PhD
  • Faculty (Planner): Linda Grinnell-Merrick, MS, NP-BC
  • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN and Bernadette Marie Makar, MSN, APRN, BC, NP-C

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Faculty (Presenter): Phillip Mease, MD, MACR

  • Consulting Fee: AbbVie, Amgen, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
  • Speakers Bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, UCB
  • Contracted Research: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB

Faculty (Presenter): Alvin F. Wells, MD, PhD, FACR

  • Speakers Bureau: AbbVie, Amgen, Alexion, Aurinia, BMS, Lilly, Novartis, Pfizer, Sanofi

Faculty (Planner): Richard Martin, MD, MA

  • Contracted Research: AbbVie, Eicos Pharmaceutical, Lilly

Faculty (Planner): Atul Deodhar, MD, MRCP, FACR, FACP

  • Consultant: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
  • Advisory Board: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
  • Contracted Research: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Physicians
Forefront Collaborative designated this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners
AANPThis activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

This activity is approved for 1.25 contact hour(s) (which includes 1.25 hour(s) of pharmacology).

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH or Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

Activity Details

Free CME/AANP
1.25 AMA PRA Category 1 Credit(s)
1.25 Contact Hour(s)
Released: April 12, 2021
Expires: April 12, 2022
75 minutes to complete

Accredited By

This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.

Target Audience

The target audience for this activity is rheumatologists and nurse practitioner (NP) and physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation in this education.

Learning Objectives

As a result of participation in this educational activity, participants should increase their ability to:

  • Summarize mechanisms of action (MOAs), effectiveness, and safety of conventional, targeted synthetic, and biologic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
  • Explain reasons to stop/delay treatment vs reasons to initiate/continue PsA treatment in elderly patients and patients with comorbidities in the context of COVID-19.
  • Discuss the role of telemedicine and other virtual strategies and tools to remotely monitor PsA progression and manage patients with PsA during and following the time of the COVID-19 pandemic.

Activity Description

The COVID-19 pandemic has added uncertainty and complexity to providing care to patients with psoriatic disease. Appropriate use of strategies and tools that support providing rheumatology care remotely is critical in today’s clinical encounters. This educational activity addresses these issues through a variety of innovative experiences. First, Dr. Philip Mease and Dr. Alvin Wells present a fascinating look at immune activation and targeted therapies in psoriatic arthritis (PsA) through augmented reality. Participants are invited to join this experience via their mobile device. The activity also features a concise overview of the latest American College of Rheumatology’s clinical practice guidelines related to COVID-19, a self-directed exercise in building and exploring patient cases, and best practices for telemedicine.

To gain the most benefit from participation in this activity, please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device. You may use one of the QR codes below or search for it in the Google Play or App Store. You may also find it helpful to download and print the worksheet from the Resources section before starting the activity.

Agenda

  1. Augmented Reality Experience: The Main Pathways of Immune Activation and Targeted Therapies in Psoriatic Arthritis
  2. Treatment of Psoriatic Arthritis During the COVID-19 Pandemic
  3. Personalized Patient Cases
  4. Telemedicine: Best Practices, and Tools to Overcome the Constraints of Distance, Location, and Time

Faculty

Philip Mease, MD, MACR
Director, Rheumatology Research
Swedish Medical Center/Providence St. Joseph Health
Clinical Professor,
University of Washington School of Medicine
Seattle, Washington


Alvin F. Wells, MD, PhD, FACR
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Director, Aurora Rheumatology and Immunotherapy Center
Franklin, Wisconsin
Adjunct Assistant Professor, Duke University Medical Center
Durham, North Carolina
Assistant Clinical Professor, Medical College of Wisconsin
Milwaukee, Wisconsin

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this activity.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Leah Johnson, Marianna Shershneva, MD, PhD
  • Faculty (Planner): Linda Grinnell-Merrick, MS, NP-BC
  • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN and Bernadette Marie Makar, MSN, APRN, BC, NP-C

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Faculty (Presenter): Phillip Mease, MD, MACR

  • Consulting Fee: AbbVie, Amgen, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
  • Speakers Bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, UCB
  • Contracted Research: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB

Faculty (Presenter): Alvin F. Wells, MD, PhD, FACR

  • Speakers Bureau: AbbVie, Amgen, Alexion, Aurinia, BMS, Lilly, Novartis, Pfizer, Sanofi

Faculty (Planner): Richard Martin, MD, MA

  • Contracted Research: AbbVie, Eicos Pharmaceutical, Lilly

Faculty (Planner): Atul Deodhar, MD, MRCP, FACR, FACP

  • Consultant: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
  • Advisory Board: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
  • Contracted Research: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Physicians
Forefront Collaborative designated this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners
AANPThis activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

This activity is approved for 1.25 contact hour(s) (which includes 1.25 hour(s) of pharmacology).

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH or Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

1.00 CME / MOC
Forefront Collaborative
Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control—Share, Learn, Engage: Setting and Achieving Treatment Targets in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control—Share, Learn, Engage: Setting and Achieving Treatment Targets in Systemic Lupus Erythematosus

Start

Activity Details

Free CME/ABIM MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Part II Points
Released: April 9, 2021
Expires: April 9, 2022
60 minutes to complete

Accredited By

Target Audience

The primary target audience for the proposed initiative is rheumatologists who practice in the United States (US) and outside the US. Other rheumatology providers and other clinicians who treat patients with systemic lupus erythematosus (SLE) can benefit from participation.

Learning Objectives

As a result of participation in this activity, participants should increase their ability to:

  • Utilize a treat-to-target approach to individualize treatment in patients with SLE.
  • Improve assessment of SLE disease activity and achievement of treatment goals.
  • Employ patient engagement strategies and shared decision making to discuss with patients their perceptions of disease, treatment goals, and benefit/risk profiles of SLE treatment options.

Activity Description

In this 60-minute activity, participants will improve their ability to assess systemic lupus erythematosus (SLE) disease activity and treatment outcomes by viewing presentations, engaging in a case study, and exploring various measures in a matching exercise. This activity will also help bridge the gap between patients’ perceptions of their disease and healthcare providers’ assessment. The SLE clinical expert and the patient will demonstrate effective patient engagement strategies—in particular, shared decision making using a decision aid—to achieve optimal, measurable therapeutic outcomes that advance care for patients living with SLE.

Faculty

Sheetal Desai, MD, MSEd
Chief of Rheumatology,
Rheumatology Fellowship Program Director,
Director, Lupus Clinic
Associate Clinical Professor of Medicine,
Division of Rheumatology
University of California, Irvine
Irvine, California


Maria Dall’Era, MD
Professor and Chief, Division of Rheumatology
Jean S. Engleman Distinguished Professorship in Rheumatology,
Director, Lupus Clinic and Rheumatology Clinical Research Center
Department of Medicine
University of California, San Francisco
San Francisco, California

Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Marianna Shershneva, PhD, Megan Ragan
  • Presenters: Maria Dall’Era, MD, Aileen Olivares

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Presenter: Sheetal Desai, MD, MSEd
    • Advisory Board: Janssen, GlaxoSmithKline
    • Speakers Bureau: Janssen, GlaxoSmithKline

CME Content Review

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

ACCME: Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™; physicians should claim only the creditcommensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Activity Details

Free CME/ABIM MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Part II Points
Released: April 9, 2021
Expires: April 9, 2022
60 minutes to complete

Accredited By

Target Audience

The primary target audience for the proposed initiative is rheumatologists who practice in the United States (US) and outside the US. Other rheumatology providers and other clinicians who treat patients with systemic lupus erythematosus (SLE) can benefit from participation.

Learning Objectives

As a result of participation in this activity, participants should increase their ability to:

  • Utilize a treat-to-target approach to individualize treatment in patients with SLE.
  • Improve assessment of SLE disease activity and achievement of treatment goals.
  • Employ patient engagement strategies and shared decision making to discuss with patients their perceptions of disease, treatment goals, and benefit/risk profiles of SLE treatment options.

Activity Description

In this 60-minute activity, participants will improve their ability to assess systemic lupus erythematosus (SLE) disease activity and treatment outcomes by viewing presentations, engaging in a case study, and exploring various measures in a matching exercise. This activity will also help bridge the gap between patients’ perceptions of their disease and healthcare providers’ assessment. The SLE clinical expert and the patient will demonstrate effective patient engagement strategies—in particular, shared decision making using a decision aid—to achieve optimal, measurable therapeutic outcomes that advance care for patients living with SLE.

Faculty

Sheetal Desai, MD, MSEd
Chief of Rheumatology,
Rheumatology Fellowship Program Director,
Director, Lupus Clinic
Associate Clinical Professor of Medicine,
Division of Rheumatology
University of California, Irvine
Irvine, California


Maria Dall’Era, MD
Professor and Chief, Division of Rheumatology
Jean S. Engleman Distinguished Professorship in Rheumatology,
Director, Lupus Clinic and Rheumatology Clinical Research Center
Department of Medicine
University of California, San Francisco
San Francisco, California

Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Marianna Shershneva, PhD, Megan Ragan
  • Presenters: Maria Dall’Era, MD, Aileen Olivares

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Presenter: Sheetal Desai, MD, MSEd
    • Advisory Board: Janssen, GlaxoSmithKline
    • Speakers Bureau: Janssen, GlaxoSmithKline

CME Content Review

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

ACCME: Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™; physicians should claim only the creditcommensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

1.25 AANP / CME / MOC
Vindico Medical Education
Interstitial Lung Disease Forum 2021: A Look at the Latest Evidence and Future Perspectives—Session 1

Interstitial Lung Disease Forum 2021: A Look at the Latest Evidence and Future Perspectives—Session 1

Start

Activity Details

Free CME/MOC/AANP
1.25 AMA PRA Category 1 Credit(s)™/
ABIM MOC Credit/AANP Credit
Released: March 31, 2021
Expires: March 30, 2022
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, rheumatologists, internists, radiologists, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with interstitial lung disease (ILD).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Apply the latest technologies and guidelines to the timely recognition of patients with ILD as well as the accurate determination of subtype.
  • Apply knowledge of the latest long-term and real-world evidence to the early and sustained treatment of patients with IPF.
  • Assess the latest clinical evidence regarding the treatment of patients with ILD.

Activity Description

Interstitial lung disease (ILD) encompasses a large group of pulmonary conditions characterized by tissue scarring, or fibrosis. Lung damage associated with ILD is often irreversible and may be progressive. Various causes have been identified, including long-term exposure to hazardous materials (e.g., asbestos); bacterial, viral, and fungal infections; and autoimmune connective tissue diseases affecting the lung. In some cases, the underlying cause remains unidentified. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, but there is a large and diverse group of patients who develop a progressive fibrosing phenotype of ILD (PF-ILD) who do not meet IPF diagnostic criteria but have a similar natural history and prognosis. Historically, treatment options for ILD have been limited, but new agents and indications have been approved in recent years. It is critical that pulmonologists, rheumatologists, and other providers who care for patients with ILD are aware of the latest clinical evidence on optimal treatment approaches for various ILD subtypes. In this two-part educational series including clinical cases, expert clinicians will discuss the latest evidence-based approaches to diagnosis, classification, and management of patients with ILD. Faculty also will review clinical trial and real-world data to support optimal treatment and improved outcomes for patients with ILD.

Agenda

Introduction
Steven D. Nathan, MD

Understanding IPF and Non-IPF ILDs: What’s New in Diagnosis and Classification
Lisa H. Lancaster, MD

Long-Term and Real-World Studies in IPF – What Can We Learn?
Robert J. Kaner, MD

Clinical Cases
Lisa H. Lancaster, MD, and Robert J. Kaner, MD

Activity Chair

Steven D. Nathan, MD
Medical Director
Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, VA

Disclosures:
Consulting Fee: Altavant, Bellerophon, Boehringer Ingelheim, Galapagos, Roche/Genentech, United Therapeutics
Speakers Bureau:
Boehringer Ingelheim, Roche/Genentech

Faculty

Robert J. Kaner, MD
Associate Professor of Clinical Medicine
Associate Professor of Genetic Medicine
Weill Cornell Medicine
New York, NY

Disclosures:
Consulting Fee: Boehringer Ingelheim, Galapagos, Genentech, Pliant, PureTech, United Therapeutics
Speakers Bureau: Genentech
Contracted Research: Bellerophon, Boehringer Ingelheim, Respivant, Toray


Lisa H. Lancaster, MD
Associate Professor
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN

Disclosures:
Spouse: Medtronic
Consulting Fee: AstraZeneca, DevPro Biopharma, Galapagos, Genentech, United Therapeutics, Veracyte
Speakers Bureau: Boehringer Ingelheim, Genentech
Contracted Research:
Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, FibroGen, Galapagos, Galecto, Novartis, Pliant, Respivant

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure:
No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure:
No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

This activity is approved for 1.25 contact hour(s) of continuing education (which includes 0.58 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 21034784. This activity was planned in accordance with AANP Accreditation Standards and Policies.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Genentech, Inc. and Veracyte, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC/AANP
1.25 AMA PRA Category 1 Credit(s)™/
ABIM MOC Credit/AANP Credit
Released: March 31, 2021
Expires: March 30, 2022
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, rheumatologists, internists, radiologists, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with interstitial lung disease (ILD).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Apply the latest technologies and guidelines to the timely recognition of patients with ILD as well as the accurate determination of subtype.
  • Apply knowledge of the latest long-term and real-world evidence to the early and sustained treatment of patients with IPF.
  • Assess the latest clinical evidence regarding the treatment of patients with ILD.

Activity Description

Interstitial lung disease (ILD) encompasses a large group of pulmonary conditions characterized by tissue scarring, or fibrosis. Lung damage associated with ILD is often irreversible and may be progressive. Various causes have been identified, including long-term exposure to hazardous materials (e.g., asbestos); bacterial, viral, and fungal infections; and autoimmune connective tissue diseases affecting the lung. In some cases, the underlying cause remains unidentified. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, but there is a large and diverse group of patients who develop a progressive fibrosing phenotype of ILD (PF-ILD) who do not meet IPF diagnostic criteria but have a similar natural history and prognosis. Historically, treatment options for ILD have been limited, but new agents and indications have been approved in recent years. It is critical that pulmonologists, rheumatologists, and other providers who care for patients with ILD are aware of the latest clinical evidence on optimal treatment approaches for various ILD subtypes. In this two-part educational series including clinical cases, expert clinicians will discuss the latest evidence-based approaches to diagnosis, classification, and management of patients with ILD. Faculty also will review clinical trial and real-world data to support optimal treatment and improved outcomes for patients with ILD.

Agenda

Introduction
Steven D. Nathan, MD

Understanding IPF and Non-IPF ILDs: What’s New in Diagnosis and Classification
Lisa H. Lancaster, MD

Long-Term and Real-World Studies in IPF – What Can We Learn?
Robert J. Kaner, MD

Clinical Cases
Lisa H. Lancaster, MD, and Robert J. Kaner, MD

Activity Chair

Steven D. Nathan, MD
Medical Director
Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, VA

Disclosures:
Consulting Fee: Altavant, Bellerophon, Boehringer Ingelheim, Galapagos, Roche/Genentech, United Therapeutics
Speakers Bureau:
Boehringer Ingelheim, Roche/Genentech

Faculty

Robert J. Kaner, MD
Associate Professor of Clinical Medicine
Associate Professor of Genetic Medicine
Weill Cornell Medicine
New York, NY

Disclosures:
Consulting Fee: Boehringer Ingelheim, Galapagos, Genentech, Pliant, PureTech, United Therapeutics
Speakers Bureau: Genentech
Contracted Research: Bellerophon, Boehringer Ingelheim, Respivant, Toray


Lisa H. Lancaster, MD
Associate Professor
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN

Disclosures:
Spouse: Medtronic
Consulting Fee: AstraZeneca, DevPro Biopharma, Galapagos, Genentech, United Therapeutics, Veracyte
Speakers Bureau: Boehringer Ingelheim, Genentech
Contracted Research:
Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, FibroGen, Galapagos, Galecto, Novartis, Pliant, Respivant

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure:
No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure:
No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

This activity is approved for 1.25 contact hour(s) of continuing education (which includes 0.58 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 21034784. This activity was planned in accordance with AANP Accreditation Standards and Policies.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Genentech, Inc. and Veracyte, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.50 CME
Vindico Medical Education
Flu in the Rheum! Managing Influenza Infection: A GameON! Challenge

Flu in the Rheum! Managing Influenza Infection: A GameON! Challenge

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: February 17, 2021
Expires: February 16, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the burden and complications resulting from influenza and how they may affect patients who are immunocompromised and/or immunosuppressed.
  • Utilize evidence-based algorithms when interpreting the results of diagnostic tests for influenza.
  • Incorporate the most appropriate influenza treatment regimen in patients at high risk for complications, based on evidence of the regimen’s safety and efficacy in these patients.

Activity Description

Influenza places a substantial burden on the health of both children and adults in the United States each year. While immunization helps to prevent flu infection, there is a need for improved treatments, preventative measures, and better mitigation for the impact associated with a pandemic, especially in high-risk patients who have comorbid illnesses or who are immunocompromised. In particular, patients with rheumatic disorders are highly vulnerable to infections because of abnormalities in their immune system, and the immunosuppressive effects of their medications. They are a high-risk group for influenza virus infection as well as for complications from the virus. Therefore, it is important that rheumatology providers are competent in their management of patients who have a rheumatic disease and are either exposed to or contract influenza. In this GameOn! educational activity, knowledge will be tested on the latest updates in the diagnosis and management of influenza.

Faculty

Cassandra Calabrese, DO
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie
Speakers Bureau: Regeneron

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Vindico Medical Education staff have no relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the questions. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: February 17, 2021
Expires: February 16, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the burden and complications resulting from influenza and how they may affect patients who are immunocompromised and/or immunosuppressed.
  • Utilize evidence-based algorithms when interpreting the results of diagnostic tests for influenza.
  • Incorporate the most appropriate influenza treatment regimen in patients at high risk for complications, based on evidence of the regimen’s safety and efficacy in these patients.

Activity Description

Influenza places a substantial burden on the health of both children and adults in the United States each year. While immunization helps to prevent flu infection, there is a need for improved treatments, preventative measures, and better mitigation for the impact associated with a pandemic, especially in high-risk patients who have comorbid illnesses or who are immunocompromised. In particular, patients with rheumatic disorders are highly vulnerable to infections because of abnormalities in their immune system, and the immunosuppressive effects of their medications. They are a high-risk group for influenza virus infection as well as for complications from the virus. Therefore, it is important that rheumatology providers are competent in their management of patients who have a rheumatic disease and are either exposed to or contract influenza. In this GameOn! educational activity, knowledge will be tested on the latest updates in the diagnosis and management of influenza.

Faculty

Cassandra Calabrese, DO
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie
Speakers Bureau: Regeneron

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Vindico Medical Education staff have no relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the questions. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.00 CME
Annenberg Center for Health Sciences at Eisenhower
Research Updates in Gout: Improving Response Rate to Therapy

Research Updates in Gout: Improving Response Rate to Therapy

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: February 12, 2021
Expires: February 11, 2022
60 minutes to complete

Accredited By

Target Audience

Rheumatologists, nephrologists, and other healthcare professionals involved in the care of patients with gout.

Learning Objectives

  • Summarize the latest evidence related to combination pharmacologic treatment of patients with gout who do not achieve the target serum urate level with monotherapy
  • Summarize the latest evidence related to complications associated with gout
  • Incorporate evidence-based research into clinical practice

Activity Description

OVERVIEW
Dr. Brian Mandell and Dr. Naomi Schlesinger discuss recent published evidence related to gout, as well as study results presented at the American College of Rheumatology Convergence 2020 virtual annual meeting. Dr. Schlesinger begins with an introduction to this CME activity by touching on a recent published systematic review indicating that the manifestations of gout extend beyond the joints, affecting other organs and tissues. Dr. Schlesinger also provides an overview of some of the challenges encountered in clinical practice with the use of urate-lowering therapy. In module 1, Dr. Schlesinger focuses on 2 abstracts presented at ACR Convergence 2020 concerning gout-related comorbidities, particularly cardiovascular disease. In module 2, Dr. Mandell focuses on 2 abstracts related to the safety and use of urate-lowering therapy, specifically allopurinol, febuxostat, and pegloticase. In module 3, Dr. Mandell discusses 2 abstracts related to the systemic nature of gout; 1 abstract focuses on heart failure, while the other focuses on the lumbar spine.

CONTENT AREAS

  • Systemic burden of gout
  • Gout comorbidities
  • Allopurinol
  • Febuxostat
  • Pegloticase

Statement of Educational Need

  • Increased understanding of the safety and efficacy of combination treatment with medications with different mechanisms for lowering the serum urate level
  • Increased understanding of updated recommendations regarding the use of combination urate-lowering therapy
  • Increased understanding of the association of gout with systemic complications involving the heart, kidneys, and other organs

Agenda

Modules will be structured and recorded in a manner that best supports the nature of the data published by each study. In general, this structure will be:

  1. Faculty welcomes the learner, introduces the study, states why the study was included in this program [1 min]
  2. Faculty reviews study methodology [1 min]
    1. For emphasis or clarity, charts, graphs, or PowerPoint slides may be edited into the final video
  3. Faculty summarizes key findings [3-4 min]
    1. How the data advances the current treatment landscape/paradigms
    2. How the data should be positioned among ongoing research
    3. How the data connects with current research imperatives
    4. Clinical significance/implications for current knowledge or practice
    5. Data one might be expected from the trial in the future
  4. Faculty provides commentary [5-8 min]

Note: this structure may vary slightly when two smaller studies or abstracts are presented in the same module.

Faculty

Brian Mandell, MD, PhD
Professor of Medicine
Chairman of Academic Medicine
Cleveland Clinic
Cleveland, Ohio


Naomi Schlesinger, MD
Professor of Medicine
Chief, Division of Rheumatology
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey

Conflict of Interest Policy/Disclosure Statement

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Faculty
Brian Mandell, MD, PhD
Consultant: Horizon
Data Monitoring Safety Board: Horizon
Speakers Bureau: Genentech

Naomi Schlesinger, MD
Advisory Board: IFM, Johnson and Johnson
Research Support: Amgen, Pfizer
Speakers Bureau: Horizon

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.

The estimated time to complete the activity is 1.0 hour.

Statement of Commercial Support

This activity is supported by an educational grant from Horizon Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.

Additional content planners
The following have no significant relationship to disclose:
Greg Scott, PharmD (Medical writer)
Eugene Cullen, MD (Peer Reviewer)

Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Contact Information for Questions About the Activity

For help or questions about this activity please contact Continuing Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: February 12, 2021
Expires: February 11, 2022
60 minutes to complete

Accredited By

Target Audience

Rheumatologists, nephrologists, and other healthcare professionals involved in the care of patients with gout.

Learning Objectives

  • Summarize the latest evidence related to combination pharmacologic treatment of patients with gout who do not achieve the target serum urate level with monotherapy
  • Summarize the latest evidence related to complications associated with gout
  • Incorporate evidence-based research into clinical practice

Activity Description

OVERVIEW
Dr. Brian Mandell and Dr. Naomi Schlesinger discuss recent published evidence related to gout, as well as study results presented at the American College of Rheumatology Convergence 2020 virtual annual meeting. Dr. Schlesinger begins with an introduction to this CME activity by touching on a recent published systematic review indicating that the manifestations of gout extend beyond the joints, affecting other organs and tissues. Dr. Schlesinger also provides an overview of some of the challenges encountered in clinical practice with the use of urate-lowering therapy. In module 1, Dr. Schlesinger focuses on 2 abstracts presented at ACR Convergence 2020 concerning gout-related comorbidities, particularly cardiovascular disease. In module 2, Dr. Mandell focuses on 2 abstracts related to the safety and use of urate-lowering therapy, specifically allopurinol, febuxostat, and pegloticase. In module 3, Dr. Mandell discusses 2 abstracts related to the systemic nature of gout; 1 abstract focuses on heart failure, while the other focuses on the lumbar spine.

CONTENT AREAS

  • Systemic burden of gout
  • Gout comorbidities
  • Allopurinol
  • Febuxostat
  • Pegloticase

Statement of Educational Need

  • Increased understanding of the safety and efficacy of combination treatment with medications with different mechanisms for lowering the serum urate level
  • Increased understanding of updated recommendations regarding the use of combination urate-lowering therapy
  • Increased understanding of the association of gout with systemic complications involving the heart, kidneys, and other organs

Agenda

Modules will be structured and recorded in a manner that best supports the nature of the data published by each study. In general, this structure will be:

  1. Faculty welcomes the learner, introduces the study, states why the study was included in this program [1 min]
  2. Faculty reviews study methodology [1 min]
    1. For emphasis or clarity, charts, graphs, or PowerPoint slides may be edited into the final video
  3. Faculty summarizes key findings [3-4 min]
    1. How the data advances the current treatment landscape/paradigms
    2. How the data should be positioned among ongoing research
    3. How the data connects with current research imperatives
    4. Clinical significance/implications for current knowledge or practice
    5. Data one might be expected from the trial in the future
  4. Faculty provides commentary [5-8 min]

Note: this structure may vary slightly when two smaller studies or abstracts are presented in the same module.

Faculty

Brian Mandell, MD, PhD
Professor of Medicine
Chairman of Academic Medicine
Cleveland Clinic
Cleveland, Ohio


Naomi Schlesinger, MD
Professor of Medicine
Chief, Division of Rheumatology
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey

Conflict of Interest Policy/Disclosure Statement

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Faculty
Brian Mandell, MD, PhD
Consultant: Horizon
Data Monitoring Safety Board: Horizon
Speakers Bureau: Genentech

Naomi Schlesinger, MD
Advisory Board: IFM, Johnson and Johnson
Research Support: Amgen, Pfizer
Speakers Bureau: Horizon

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.

The estimated time to complete the activity is 1.0 hour.

Statement of Commercial Support

This activity is supported by an educational grant from Horizon Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.

Additional content planners
The following have no significant relationship to disclose:
Greg Scott, PharmD (Medical writer)
Eugene Cullen, MD (Peer Reviewer)

Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Contact Information for Questions About the Activity

For help or questions about this activity please contact Continuing Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday

Pages